0000000000336262

AUTHOR

Miquel Bioque

showing 7 related works from this author

Gene-environment interaction as a predictor of early adjustment in first episode psychosis.

2017

Abstract Background This study aims to explore the gene-environment interaction hypothesis applied to pre-symptomatic neurodevelopmental phenotypes of first episode psychosis (FEP), that is, genetic factors might increase vulnerability to the effects of environmental adverse conditions occurring at later stages of development. Methods We constructed a schematic ‘two-hit’ model, with Val/Val homozygosity for the catechol- O -methyltransferase ( COMT ) Val158Met polymorphism as the ‘first hit’ and history of obstetric complications and parental socioeconomic status as ‘second hits’. Early adjustment, measured using the Premorbid Adjustment Scale, was considered the main outcome. The study pop…

AdultMaleParentsmedicine.medical_specialtyGenotypePremorbid Adjustment ScaleCatechol O-MethyltransferasePolymorphism Single NucleotideStatistics Nonparametric03 medical and health sciencesYoung Adult0302 clinical medicineMethioninePolymorphism (computer science)First episode psychosismedicineHumansGenetic Predisposition to DiseaseGene–environment interactionPsychiatrySocioeconomic statusBiological PsychiatryRetrospective StudiesAdverse conditionsValinemedicine.disease030227 psychiatryPsychiatry and Mental healthPsychotic DisordersSchizophreniaPopulation studyFemaleGene-Environment InteractionPsychology030217 neurology & neurosurgeryDemographySchizophrenia research
researchProduct

Age at First Episode Modulates Diagnosis-Related Structural Brain Abnormalities in Psychosis.

2016

Brain volume and thickness abnormalities have been reported in first-episode psychosis (FEP). However, it is unclear if and how they are modulated by brain developmental stage (and, therefore, by age at FEP as a proxy). This is a multicenter cross-sectional case-control brain magnetic resonance imaging (MRI) study. Patients with FEP (n = 196), 65.3% males, with a wide age at FEP span (12-35 y), and healthy controls (HC) (n = 157), matched for age, sex, and handedness, were scanned at 6 sites. Gray matter volume and thickness measurements were generated for several brain regions using FreeSurfer software. The nonlinear relationship between age at scan (a proxy for age at FEP in patients) and…

Cingulate cortexAdultMalemedicine.medical_specialtyAdolescentBipolar disorderCortical thicknessTemporal lobe03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicineHumansAge of OnsetGray MatterChildTemporal cortexFirst episodeCerebral CortexParietal lobeAge FactorsAge at onsetRegular ArticleCortical volumeFirst-episode psychosisMagnetic Resonance Imaging030227 psychiatryPsychiatry and Mental healthCross-Sectional StudiesFrontal lobePsychotic DisordersCase-Control StudiesBrain sizeCardiologySchizophreniaFemaleAge of onsetPsychologyNeuroscience030217 neurology & neurosurgeryMRISchizophrenia bulletin
researchProduct

Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis.

2018

Background: Hyperprolactinemia is a common side-effect of antipsychotics (APs), which may trigger serious secondary problems and compromise the adherence to treatment which is crucial for prognosis, especially in patients presenting with a first-episode of psychosis (FEP). Aims: We evaluated, in some cases for the first time, the effect of polymorphisms in multiple candidate genes on serum prolactin (PRL) levels in an AP-treated FEP cohort recruited in the multicenter PEPs study (Phenotype − genotype and environmental interaction; Application of a predictive model in first psychotic episodes). Methods: PRL concentration was measured in serum from 222 patients. A total of 167 polymorphisms w…

AdultMalePsychosismedicine.medical_specialtyCandidate geneSerotoninSide effectAdolescentmedicine.medical_treatmentDopaminePeptidyl-Dipeptidase A03 medical and health sciencesYoung Adult0302 clinical medicineDopaminePolymorphism (computer science)Internal medicinemedicineHumansReceptor trkBPharmacology (medical)AntipsychoticPharmacologyMembrane GlycoproteinsPolymorphism Geneticbusiness.industryReceptors Dopamine D2medicine.diseaseProlactin030227 psychiatryProlactinHyperprolactinemiaPsychiatry and Mental healthEndocrinologyPsychotic DisordersCohortFemalebusiness030217 neurology & neurosurgerymedicine.drugAntipsychotic AgentsJournal of psychopharmacology (Oxford, England)
researchProduct

Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis

2019

This work was supported by the Carlos III Institute of Health and European Fund for Regional Development (PI08/1213, PI11/01977, PI14/01900, PI08/01026, PI11/02831, PI14/01621, PI08/1161, PI16/00359, PI16/01164, PI18/00805), the Basque Foundation for Health Innovation and Research (BIOEF), the Secretaria d´Universitats I Recerca del Departament d´Economia I Coneixement (2017 SGR 1365), and R&D activities in Biomedicine, Madrid Regional Government and Structural Funds of the European Union (S2017/BMD-3740 (AGES-CM 2-CM)).

AdultMaleFirst episode psychosisAdolescentSocial perceptionPsicosiCognitive reservesocial cognitionNeuropsychological TestsPercepció socialPsychosocial functioning03 medical and health sciencesYoung Adult0302 clinical medicineMediatorSocial cognitionfirst episode psychosisHumansPath analysis (statistics)Applied PsychologyCognitive reservePsychiatric Status Rating ScalesMediation AnalysisPsychosesCognitionSocial cognition030227 psychiatryPsychiatry and Mental healthPsychotic DisordersLinear Modelspsychosocial functioningFemaleVerbal memoryCognitive reserve first episode psychosis psychosocial functioning social cognitionPsychologyNeurocognitivePsychosocial030217 neurology & neurosurgeryClinical psychology
researchProduct

Smoking does not impact social and non-social cognition in patients with first episode psychosis.

2018

Abstract Background Many studies having shown significant improvements in non-social and social cognitive performance in smoking FEP patients compared to non-smoking FEP patients. The findings are controversial. This study analyzed the effects of tobacco use on non-social and social cognitive function in a large group of FEP patients and a matched healthy control group. Methods A sample of 335 patients with FEP and 253 healthy controls was divided into four subgroups: control tobacco users (CTU), control non-tobacco users (CNTU), patient tobacco users (PTU) and patient non-tobacco users (PNTU). Demographic variables, tobacco use variables (presence or absence, frequency and duration of toba…

AdultMaleAdolescent03 medical and health sciencesExecutive FunctionYoung Adult0302 clinical medicineCognitionSocial cognitionFirst episode psychosismedicineTobacco SmokingHumansLongitudinal StudiesProspective StudiesChildSocial BehaviorBiological PsychiatryWorking memorybusiness.industryCognitionTobacco Use DisorderExecutive functionsmedicine.disease030227 psychiatryPsychiatry and Mental healthCross-Sectional StudiesMemory Short-TermPsychotic DisordersSchizophreniaFemalebusinessNeurocognitive030217 neurology & neurosurgerySocial cognitive theoryClinical psychologySchizophrenia research
researchProduct

jop-2017-3257-File006 – Supplemental material for Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients w…

2018

Supplemental material, jop-2017-3257-File006 for Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis by Patricia Gassó, Sergi Mas, Miquel Bioque, Bibiana Cabrera, Antonio Lobo, Ana González-Pinto, Covadonga M. Díaz-Caneja, Iluminada Corripio, Eduard Vieta, Josefina Castro-Fornieles, Salvador Sarró, Anna Mané, Julio Sanjuan, Adrián Llerena, Amalia Lafuente, Jerónimo Saiz-Ruiz, Miguel Bernardo and PEPs Group in Journal of Psychopharmacology

FOS: PsychologyFOS: Clinical medicine170199 Psychology not elsewhere classified110319 Psychiatry (incl. Psychotherapy)111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified110904 Neurology and Neuromuscular Diseases
researchProduct

jop-2017-3257-File005 – Supplemental material for Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients w…

2018

Supplemental material, jop-2017-3257-File005 for Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis by Patricia Gassó, Sergi Mas, Miquel Bioque, Bibiana Cabrera, Antonio Lobo, Ana González-Pinto, Covadonga M. Díaz-Caneja, Iluminada Corripio, Eduard Vieta, Josefina Castro-Fornieles, Salvador Sarró, Anna Mané, Julio Sanjuan, Adrián Llerena, Amalia Lafuente, Jerónimo Saiz-Ruiz, Miguel Bernardo and PEPs Group in Journal of Psychopharmacology

FOS: PsychologyFOS: Clinical medicine170199 Psychology not elsewhere classified110319 Psychiatry (incl. Psychotherapy)111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified110904 Neurology and Neuromuscular Diseases
researchProduct